ClinicalTrials.gg
CompletedNCT05802862Updated May 1, 2026

A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China

A Phase 3 interventional study of Insulin Degludec and Insulin Aspart in Diabetes, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
414
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies testing insulin degludec in Diabetes Mellitus — 1 open to participants now, 1 under way, 1 of them phase 3. insulin degludec · Diabetes Mellitus.

Enrollment
33rd of 103
414 · median 145
Started
2023
with 1 other
Phase 3
55 of 103
1 open now
Registered
102nd of 103
by date
Lead sponsor
1 of 103
Sunshine Lake Pharma Co., Ltd.

Among the 103 studies testing insulin degludec in Diabetes Mellitus, this one is the 33rd largest by enrollment, is one of 2 that started in 2023, is one of 55 in phase 3, and was the 102nd registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 103 studies testing insulin degludec in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies testing insulin degludec in Diabetes Mellitus, or all of them as a file.
02

Study summary

The purpose of this study is to see if Insulin Degludec/Insulin Aspart (22011) compared to Insulin Degludec/Insulin Aspart (Ryzodeg) is similar in safety and effect in participants with type 2 diabetes (T2D).

03

Conditions studied

  • Diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities.
  • Male or female, age at least 18 year-old and no more than 75 year-old at the time of signing informed consent.
  • Type 2 diabetes mellitus (T2D).
  • (BMI) higher than 18.0, but below or equal to 35.0 kg/m\^2.
  • Current treatment for at least 3 months prior to screening with basal insulin/premixed insulin once a day or twice a day with/without oral anti-diabetic drugs (OADs): metformin, alpha-glucosidase inhibitors, dimethylphenylpenicillin dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-dependent glucose transporter 2 (SGLT-2) inhibitors . For above or equal to 3 months prior to screening subjects should be on a stable dose.
  • from 7-11.0% both inclusive at screening confirmed by central laboratory analysis.

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of type 1 diabetes (T1D), or specific type of diabetes other than T2D, for example, injured pancreas, diseases of acromegaly-induced diabetes.
  • Have a history of ketoacidosis or hyperosmolar state or coma requiring hospitalization within 6 months prior to screening.
  • Have had severe hypoglycemia episodes within 6 months prior to screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
414 participants (actual)

Study arms

  • Experimental
    22011

    Drug: Insulin Degludec and Insulin Aspart

  • Active comparator
    Ryzodeg

    Drug: Insulin Degludec and Insulin Aspart

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) in Week 12

    HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time

    Time frame: Baseline to Week12

  2. Percentage of Participant Who Achieved HbA1c<7% and ≤6.5%

    the ratio of participant Who Achieved HbA1c\<7% and ≤6.5%

    Time frame: Baseline to Week24

  3. Percentage of Participant Who Achieved HbA1c<7% and ≤6.5% without Hypoglycaemic Episodes

    The ratio of participant Who Achieved HbA1c\<7% and ≤6.5% without Hypoglycaemic Episodes

    Time frame: Baseline to Week24

  4. Change From Baseline in Fasting Plasma Glucose(FPG)

    the plasma glucose concentration on an empty stomach

    Time frame: Baseline to Week12

  5. Change From Baseline in Fasting Plasma Glucose(FPG) in Week24

    the plasma glucose concentration on an empty stomach

    Time frame: Baseline to Week24

  6. Change From Baseline in 7-Point Self-Monitoring Blood Glucose (SMBG) Values

    SMBG 7-point profiles were measured at fasting, 2-hour post morning meal, pre midday meal, 2-hour post midday meal, pre evening meal, 2-hours post evening meal, and bedtime.

    Time frame: Baseline to Week12

  7. Change From Baseline in 7-Point Self-Monitoring Blood Glucose (SMBG) Values in Week24

    SMBG 7-point profiles were measured at fasting, 2-hour post morning meal, pre midday meal, 2-hour post midday meal, pre evening meal, 2-hours post evening meal, and bedtime.

    Time frame: Baseline to Week24

  8. Change From Baseline in Body weight

    Change in body weight

    Time frame: Baseline to Week24

  9. Number of Treatment-emergent Adverse Events (TEAE) and Serious Adverse Events(SAE)

    Safety

    Time frame: from baseline to Week25

07

Study locations

1 site
  • Sunshine Lake Pharma Co., Ltd.
    Dongguan, Guangdong 523000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Aug 2024, 13 months.

Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 13 months is below that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Apr 7, 2023
StartActual
Jul 6, 2023
Primary completionActual
Aug 16, 2024
CompletionActual
Aug 16, 2024
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05802862
Responsible party
Sponsor
First posted
Apr 7, 2023
Start date
Jul 6, 2023
Primary completion
Aug 16, 2024
Completion
Aug 16, 2024
Last update
May 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Aspart

Start the discussion